Ophthalmology AdvisorSurgery Outperforms Meds in Advanced Glaucoma Visual Field Preservation

The TAGS trial randomized 453 adults across 27 UK glaucoma centers to trabeculectomy or medications-first management. Index-eye visual field loss rates were 0.37 dB/year in the surgical group versus 0.75 dB/year in the medication group (P=.002), with binocular integrated VF trending in the same direction without reaching significance.

Clinical Considerations:

• Trabeculectomy produced ~50% slower VF decay in index eyes over 5 years compared with medical management
• QoL instruments (VFQ-25) did not differentiate between groups, likely due to better-eye dominance buffering perception of monocular progression
• Researchers estimate a clinically important VFQ-25 difference would require ~23 years of follow-up — beyond any practical trial window
• Study authors recommend VF as the primary outcome for advanced glaucoma trials rather than QoL composites

Practice Applications:

• Consider trabeculectomy as a primary intervention in newly diagnosed advanced open-angle glaucoma rather than defaulting to sequential medical management
• Recognize that VFQ-25 scores may understate surgical benefit in monocular progression scenarios
• Interpret stable QoL scores in surgical patients as a measurement limitation, not evidence of equivalent outcomes
• Monitor evolving methodology around domain-specific QoL tools better calibrated to glaucoma progression